Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002934 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 711
- Enrollment target
NCT00002934: Clinical Trial Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00002934 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 711 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (435% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002934, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 711 participants
- Enrollment target
Study Summary
RATIONALE: The evaluation of breast cancer recurrence rates may improve the ability to plan cancer treatment for patients with breast cancer. PURPOSE: Study to evaluate the rate of recurrence of breast cancer in women who have had surgery for ductal carcinoma in situ.
Primary Outcome
Rate of in situ or invasive local breast cancer recurrence
Interventions
- PROCEDURE long-term screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 1997-06-25 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Why NCT00002934 stopped before completion
NCT00002934 is an interventional study that assigns participants to a tested intervention. The registered 711 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (435% higher).
The record links to 0 conditions, and to 1 intervention - of which long-term screening is the first listed.
NCT00002934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002934 about?
NCT00002934 is a clinical study titled "Evaluation of Breast Cancer Recurrence Rates Following Surgery in Women With Ductal Carcinoma In Situ". RATIONALE: The evaluation of breast cancer recurrence rates may improve the ability to plan cancer treatment for patients with breast cancer. PURPOSE: Study to evaluate the rate of recurrence of breast cancer in women who have had surgery for ductal carcinoma in situ.
What is the current status of trial NCT00002934?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 711 participants. The study started on 1997-06-25. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00002934?
The interventions under investigation include: long-term screening (PROCEDURE).
Who is sponsoring clinical trial NCT00002934?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002934's enrollment target sits among peer trials
711 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT06470867 · 710 participants · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI